Ida Rosenkrands
Overview
Explore the profile of Ida Rosenkrands including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Worzner K, Schmidt S, Zimmermann J, Tami A, Polacek C, Fernandez-Antunez C, et al.
EBioMedicine
. 2025 Feb;
113:105615.
PMID: 39983329
Background: Intranasal vaccines against respiratory viruses are desired due to ease of administration and potential to protect against virus infection of the upper respiratory tract. Methods: We tested a cationic...
2.
Kildemoes A, Rai O, Westermann E, Johansen H, Bjornelius E, Anagrius C, et al.
medRxiv
. 2024 Dec;
PMID: 39649584
is a sexually transmitted pathogen, which can cause a range of reproductive tract diseases in both men and women. To disentangle the relationship between infection(s) and subsequent reproductive health complications...
3.
Woodworth J, Contreras V, Christensen D, Naninck T, Kahlaoui N, Gallouet A, et al.
Nat Commun
. 2024 Oct;
15(1):8959.
PMID: 39420177
Development of new vaccines tailored for difficult-to-target diseases is hampered by a lack of diverse adjuvants for human use, and none of the currently available adjuvants induce Th17 cells. Here,...
4.
Paulet E, Contreras V, Galhaut M, Rosenkrands I, Holland M, Burton M, et al.
PLoS Negl Trop Dis
. 2024 Aug;
18(8):e0012388.
PMID: 39093884
Background: Trachoma is a leading cause of infection-related blindness worldwide. This disease is caused by recurrent Chlamydia trachomatis (Ct) infections of the conjunctiva and develops in two phases: i) active...
5.
Rosenkrands I, Olsen A, Knudsen S, Dehari N, Juel H, Cheeseman H, et al.
EBioMedicine
. 2024 May;
104:105140.
PMID: 38744110
Background: Chlamydia trachomatis (CT) Major Outer Membrane Protein (MOMP) holds a neutralising epitope in the Variable Domain 4 (VD4), and this region's immune dominance during infection is well known. This...
6.
Pollock K, Borges A, Cheeseman H, Rosenkrands I, Schmidt K, Sondergaard R, et al.
Lancet Infect Dis
. 2024 Apr;
24(8):829-844.
PMID: 38615673
Background: There is no vaccine against the major global pathogen Chlamydia trachomatis; its different serovars cause trachoma in the eye or chlamydia in the genital tract. We did a clinical...
7.
Olsen A, Rosenkrands I, Jacobsen C, Cheeseman H, Kristiansen M, Dietrich J, et al.
Nat Commun
. 2024 Feb;
15(1):1665.
PMID: 38396019
The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01...
8.
Barton A, Rosenkrands I, Pickering H, Faal N, Harte A, Joof H, et al.
Front Immunol
. 2023 Jun;
14:1178741.
PMID: 37287960
Background: Ocular infections with serovars A-C cause the neglected tropical disease trachoma. As infection does not confer complete immunity, repeated infections are common, leading to long-term sequelae such as scarring...
9.
A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
Dijkman K, Lindenstrom T, Rosenkrands I, Soe R, Woodworth J, Arlehamn C, et al.
NPJ Vaccines
. 2023 May;
8(1):66.
PMID: 37160970
The only licensed tuberculosis (TB) vaccine, Bacillus Calmette Guerin (BCG), fails to reliably protect adolescents and adults from pulmonary TB, resulting in ~1.6 million deaths annually. Protein subunit vaccines have...
10.
Woodworth J, Contreras V, Christensen D, Naninck T, Kahlaoui N, Gallouet A, et al.
bioRxiv
. 2023 Mar;
PMID: 36865310
After clean drinking water, vaccination is the most impactful global health intervention. However, development of new vaccines against difficult-to-target diseases is hampered by the lack of diverse adjuvants for human...